Logo of Proteomics International Laboratories (ASX:PIQ)Latest Proteomics International Laboratories (ASX:PIQ) News

Page 4
Page 4 of 5

Proteomics International’s Blood Test Detects Early Esophageal Cancer with High Accuracy

Proteomics International has unveiled new clinical data confirming its PromarkerEso blood test can accurately detect early stages of esophageal adenocarcinoma, potentially transforming screening for a cancer with poor prognosis.
Ada Torres
8 Sept 2025

Proteomics International’s Loss Widens Amid Promarker® Commercial Push

Proteomics International Laboratories reported a 26% increase in losses for FY2025, driven by higher operational costs as it advances its Promarker® diagnostic pipeline. Despite an 8% rise in revenue from ordinary activities, total income slipped 2%, underscoring ongoing commercialisation challenges.
Ada Torres
27 Aug 2025

Proteomics International Accelerates US Launch of PromarkerD After $12M Raise

Proteomics International Laboratories has secured $12 million to fast-track its precision diagnostic tests, including the US launch of PromarkerD for diabetic kidney disease, backed by a new AMA billing code. The company also advances its pipeline with new patents and commercial partnerships.
Ada Torres
28 July 2025

How Proteomics International’s OxiDx Test Revolutionises Racehorse Muscle Recovery

Proteomics International’s subsidiary OxiDx has unveiled a pioneering test that detects muscle damage in thoroughbred racehorses, promising to transform recovery management in the racing industry. The test’s commercial launch is slated for the second half of 2025.
Ada Torres
14 July 2025

Proteomics International Unlocks US Billing Code for Kidney Disease Test

Proteomics International has secured a dedicated US reimbursement code for its next-generation PromarkerD test, a key step towards broader adoption in diabetic kidney disease diagnostics.
Ada Torres
3 July 2025

Proteomics International Secures $6M to Revolutionize Precision Diagnostics

Proteomics International, alongside key partners, is investing $6 million to expand the WA Proteomics Facility, aiming to establish a nationally accredited platform for industrial-scale protein biomarker analysis in medicine and agriculture.
Ada Torres
1 July 2025

Proteomics International Secures First Global Patent for PromarkerEndo in Japan

Proteomics International has achieved a major milestone with the first worldwide patent granted in Japan for its PromarkerEndo blood test, designed to diagnose endometriosis early and accurately.
Ada Torres
30 June 2025

Proteomics International Unveils PromarkerD in US to Predict Diabetic Kidney Disease Early

Proteomics International has launched PromarkerD, a pioneering blood test that predicts diabetic kidney disease years before symptoms, marking its entry into the vast US healthcare market.
Ada Torres
20 June 2025

Proteomics International Doubles Down on Oversubscribed Share Purchase Plan

Proteomics International Laboratories has expanded its Share Purchase Plan offer after receiving applications exceeding $7.5 million, significantly increasing the number of new options issued.
Ada Torres
6 June 2025

Proteomics International Validates Breakthrough Blood Test for Early Esophageal Cancer Detection

Proteomics International has published clinical validation results for PromarkerEso, a novel blood test that detects esophageal adenocarcinoma with remarkable accuracy, promising a non-invasive alternative to costly and uncomfortable endoscopy procedures.
Ada Torres
5 June 2025

Proteomics International Secures $12M to Accelerate Diagnostic Test Launches

Proteomics International has completed a $12 million capital raise, including a heavily oversubscribed Share Purchase Plan, to fast-track the rollout of its innovative diagnostic tests in Australia and the USA.
Ada Torres
5 June 2025

Proteomics International Validates Breakthrough Blood Test for Endometriosis

Proteomics International has validated its PromarkerEndo blood test as a highly accurate, non-invasive diagnostic tool for endometriosis, with commercial launch planned in Australia for Q3 2025. The test promises to reduce the average seven-year diagnostic delay by providing a simple risk score applicable across all disease stages.
Ada Torres
26 May 2025